Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

1/23/26 5:25:47 PM ET

$IMVT

$ROIV

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IMVT alert in real time by email

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026.

To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call.

About Immunovant

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

Contacts:

Investors

Keyur Parekh

keyur.parekh@roivant.com

Media

Stephanie Lee

stephanie.lee@roivant.com

Get the next $IMVT alert in real time by email

Recent Analyst Ratings for

$IMVT

$ROIV

Company	Date	Price Target	Rating	Analyst
Roivant Sciences Ltd. $ROIV	3/20/2026	$35.00	Outperform	Bernstein
Immunovant Inc. $IMVT	3/20/2026	$28.00	Mkt Perform	Bernstein
Immunovant Inc. $IMVT	1/6/2026	$50.00	Peer Perform → Outperform	Wolfe Research
Immunovant Inc. $IMVT	10/14/2025	$16.00	Hold	Truist
Roivant Sciences Ltd. $ROIV	9/2/2025	$16.00	Buy	Citigroup
Roivant Sciences Ltd. $ROIV	7/10/2025	$19.00	Buy	Goldman
Immunovant Inc. $IMVT	7/10/2025	$18.00	Neutral	Goldman
Immunovant Inc. $IMVT	3/3/2025	$20.00	Hold	Jefferies

More analyst ratings

Recent Analyst Ratings for

$IMVT

$ROIV

Company	Date	Price Target	Rating	Analyst
Roivant Sciences Ltd. $ROIV	3/20/2026	$35.00	Outperform	Bernstein
Immunovant Inc. $IMVT	3/20/2026	$28.00	Mkt Perform	Bernstein
Immunovant Inc. $IMVT	1/6/2026	$50.00	Peer Perform → Outperform	Wolfe Research
Immunovant Inc. $IMVT	10/14/2025	$16.00	Hold	Truist
Roivant Sciences Ltd. $ROIV	9/2/2025	$16.00	Buy	Citigroup
Roivant Sciences Ltd. $ROIV	7/10/2025	$19.00	Buy	Goldman
Immunovant Inc. $IMVT	7/10/2025	$18.00	Neutral	Goldman
Immunovant Inc. $IMVT	3/3/2025	$20.00	Hold	Jefferies

More analyst ratings

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$IMVT
$ROIV

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$IMVT
$ROIV

$IMVT
$ROIV
Insider Purchases

Director Roivant Sciences Ltd. bought $349,999,986 worth of shares (16,666,666 units at $21.00), increasing direct ownership by 17% to 113,317,007 units (SEC Form 4)

CEO Gline Matthew bought $49,957 worth of shares (3,315 units at $15.07), increasing direct ownership by 0.02% to 17,287,081 units (SEC Form 4)

Director Roivant Sciences Ltd. bought $336,900,200 worth of shares (16,845,010 units at $20.00), increasing direct ownership by 21% to 96,650,341 units (SEC Form 4)

$IMVT
$ROIV
Press Releases

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

$IMVT
$ROIV
Leadership Updates

Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

$IMVT
$ROIV
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

SEC Form SC 13G filed by Roivant Sciences Ltd.

$IMVT
$ROIV
SEC Filings

SEC Form 144 filed by Immunovant Inc.

SEC Form S-8 filed by Roivant Sciences Ltd.

SEC Form 144 filed by Immunovant Inc.

$IMVT
$ROIV
Insider Trading

Director Fromkin Andrew J. exercised 196,601 shares at a strike of $8.22 and sold $7,438,111 worth of shares (221,951 units at $33.51), decreasing direct ownership by 25% to 74,382 units (SEC Form 4)

President & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85, sold $6,054,000 worth of shares (200,000 units at $30.27) and covered exercise/tax liability with 34,483 shares, decreasing direct ownership by 2% to 1,613,063 units (SEC Form 4) (withholding obligation)

CFO Pulik Richard covered exercise/tax liability with 18,962 shares, decreasing direct ownership by 6% to 278,549 units (SEC Form 4) to satisfy withholding tax

$IMVT
$ROIV
Analyst Ratings

Bernstein initiated coverage on Roivant Sciences with a new price target

Bernstein initiated coverage on Immunovant Sciences with a new price target

Immunovant Sciences upgraded by Wolfe Research with a new price target

$IMVT
$ROIV
Financials

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $IMVT$ROIV

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $IMVT$ROIV

$IMVT$ROIV Insider Purchases

Director Roivant Sciences Ltd. bought $349,999,986 worth of shares (16,666,666 units at $21.00), increasing direct ownership by 17% to 113,317,007 units (SEC Form 4)

CEO Gline Matthew bought $49,957 worth of shares (3,315 units at $15.07), increasing direct ownership by 0.02% to 17,287,081 units (SEC Form 4)

Director Roivant Sciences Ltd. bought $336,900,200 worth of shares (16,845,010 units at $20.00), increasing direct ownership by 21% to 96,650,341 units (SEC Form 4)

$IMVT$ROIV Press Releases

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

$IMVT$ROIV Leadership Updates

Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

$IMVT$ROIV Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

SEC Form SC 13G filed by Roivant Sciences Ltd.

$IMVT$ROIV SEC Filings

SEC Form 144 filed by Immunovant Inc.

SEC Form S-8 filed by Roivant Sciences Ltd.

SEC Form 144 filed by Immunovant Inc.

$IMVT$ROIV Insider Trading

Director Fromkin Andrew J. exercised 196,601 shares at a strike of $8.22 and sold $7,438,111 worth of shares (221,951 units at $33.51), decreasing direct ownership by 25% to 74,382 units (SEC Form 4)

President & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85, sold $6,054,000 worth of shares (200,000 units at $30.27) and covered exercise/tax liability with 34,483 shares, decreasing direct ownership by 2% to 1,613,063 units (SEC Form 4) (withholding obligation)

CFO Pulik Richard covered exercise/tax liability with 18,962 shares, decreasing direct ownership by 6% to 278,549 units (SEC Form 4) to satisfy withholding tax

$IMVT$ROIV Analyst Ratings

Bernstein initiated coverage on Roivant Sciences with a new price target

Bernstein initiated coverage on Immunovant Sciences with a new price target

Immunovant Sciences upgraded by Wolfe Research with a new price target

$IMVT$ROIV Financials

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

Recent Analyst Ratings for
$IMVT
$ROIV

Recent Analyst Ratings for
$IMVT
$ROIV

$IMVT
$ROIV
Insider Purchases

$IMVT
$ROIV
Press Releases

$IMVT
$ROIV
Leadership Updates

$IMVT
$ROIV
Large Ownership Changes

$IMVT
$ROIV
SEC Filings

$IMVT
$ROIV
Insider Trading

$IMVT
$ROIV
Analyst Ratings

$IMVT
$ROIV
Financials